Literature DB >> 22806355

Systemic inflammation in childhood obesity: circulating inflammatory mediators and activated CD14++ monocytes.

H S Schipper1,2, R Nuboer3, S Prop1, H J van den Ham4, F K de Boer5, Ç Kesmir5, I M H Mombers2, K A van Bekkum2, J Woudstra1, J H Kieft2, I E Hoefer6, W de Jager2, B Prakken2, M van Summeren7, E Kalkhoven8.   

Abstract

AIMS/HYPOTHESIS: In adults, circulating inflammatory mediators and activated CD14(++) monocytes link obesity to its metabolic and cardiovascular complications. However, it is largely unknown whether these inflammatory changes already occur in childhood obesity. To survey inflammatory changes during the early stages of obesity, we performed a comprehensive analysis of circulating inflammatory mediators, monocyte populations and their function in childhood obesity.
METHODS: In lean and obese children aged 6 to 16 years (n = 96), 35 circulating inflammatory mediators including adipokines were measured. Hierarchical cluster analysis of the inflammatory mediator profiles was performed to investigate associations between inflammatory mediator clusters and clinical variables. Whole-blood monocyte phenotyping and functional testing with the toll-like receptor 4 ligand, lipopolysaccharide, were also executed.
RESULTS: First, next to leptin, the circulating mediators chemerin, tissue inhibitor of metalloproteinase 1, EGF and TNF receptor 2 were identified as novel inflammatory mediators that are increased in childhood obesity. Second, cluster analysis of the circulating mediators distinguished two obesity clusters, two leanness clusters and one mixed cluster. All clusters showed distinct inflammatory mediator profiles, together with differences in insulin sensitivity and other clinical variables. Third, childhood obesity was associated with increased CD14(++) monocyte numbers and an activated phenotype of the CD14(++) monocyte subsets. CONCLUSIONS/
INTERPRETATION: Inflammatory mediator clusters were associated with insulin resistance in obese and lean children. The activation of CD14(++) monocyte subsets, which is associated with increased development of atherosclerosis in obese adults, was also readily detected in obese children. Our results indicate that inflammatory mechanisms linking obesity to its metabolic and cardiovascular complications are already activated in childhood obesity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22806355     DOI: 10.1007/s00125-012-2641-y

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  47 in total

1.  A multiplex immunoassay for human adipokine profiling.

Authors:  Henk S Schipper; Wilco de Jager; Mariska E A van Dijk; Jenny Meerding; Pierre M J Zelissen; Roger A Adan; Berent J Prakken; Eric Kalkhoven
Journal:  Clin Chem       Date:  2010-06-08       Impact factor: 8.327

2.  Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model.

Authors:  Hui Chen; Gail Sullivan; Michael J Quon
Journal:  Diabetes       Date:  2005-07       Impact factor: 9.461

3.  Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice.

Authors:  William L Holland; Benjamin T Bikman; Li-Ping Wang; Guan Yuguang; Katherine M Sargent; Sarada Bulchand; Trina A Knotts; Guanghou Shui; Deborah J Clegg; Markus R Wenk; Michael J Pagliassotti; Philipp E Scherer; Scott A Summers
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

4.  Monocyte heterogeneity in obesity and subclinical atherosclerosis.

Authors:  Kyrill S Rogacev; Christof Ulrich; Lutz Blömer; Florian Hornof; Katrin Oster; Maren Ziegelin; Bodo Cremers; Yvonne Grenner; Jürgen Geisel; Axel Schlitt; Hans Köhler; Danilo Fliser; Matthias Girndt; Gunnar H Heine
Journal:  Eur Heart J       Date:  2009-08-17       Impact factor: 29.983

5.  Altered plasma adipokine levels and in vitro adipocyte differentiation in pediatric type 1 diabetes.

Authors:  A A Verrijn Stuart; H S Schipper; I Tasdelen; D A Egan; B J Prakken; E Kalkhoven; W de Jager
Journal:  J Clin Endocrinol Metab       Date:  2011-11-23       Impact factor: 5.958

Review 6.  Chemerin: at the crossroads of inflammation and obesity.

Authors:  Matthew C Ernst; Christopher J Sinal
Journal:  Trends Endocrinol Metab       Date:  2010-11       Impact factor: 12.015

Review 7.  Adipokines in inflammation and metabolic disease.

Authors:  Noriyuki Ouchi; Jennifer L Parker; Jesse J Lugus; Kenneth Walsh
Journal:  Nat Rev Immunol       Date:  2011-01-21       Impact factor: 53.106

8.  Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b.

Authors:  Chaofeng Han; Jing Jin; Sheng Xu; Haibo Liu; Nan Li; Xuetao Cao
Journal:  Nat Immunol       Date:  2010-07-18       Impact factor: 25.606

9.  Establishing a standard definition for child overweight and obesity worldwide: international survey.

Authors:  T J Cole; M C Bellizzi; K M Flegal; W H Dietz
Journal:  BMJ       Date:  2000-05-06

Review 10.  Childhood obesity and risk of the adult metabolic syndrome: a systematic review.

Authors:  L J Lloyd; S C Langley-Evans; S McMullen
Journal:  Int J Obes (Lond)       Date:  2011-11-01       Impact factor: 5.095

View more
  38 in total

1.  The associations between the changes in serum inflammatory markers and bone mineral accrual in boys with overweight and obesity during pubertal maturation: a 3-year longitudinal study in Estonian boys.

Authors:  E Mengel; V Tillmann; L Remmel; P Kool; P Purge; E Lätt; J Jürimäe
Journal:  Osteoporos Int       Date:  2018-06-01       Impact factor: 4.507

Review 2.  The initiation of metabolic inflammation in childhood obesity.

Authors:  Kanakadurga Singer; Carey N Lumeng
Journal:  J Clin Invest       Date:  2017-01-03       Impact factor: 14.808

3.  Obesity is associated with acute inflammation in a sample of adolescents.

Authors:  Marcela Reyes; Cristina Quintanilla; Raquel Burrows; Estela Blanco; Mariana Cifuentes; Sheila Gahagan
Journal:  Pediatr Diabetes       Date:  2014-03-17       Impact factor: 4.866

4.  Chemerin-induced arterial contraction is Gi- and calcium-dependent.

Authors:  David J Ferland; Emma S Darios; Richard R Neubig; Benita Sjögren; Nguyen Truong; Rosa Torres; Thomas S Dexheimer; Janice M Thompson; Stephanie W Watts
Journal:  Vascul Pharmacol       Date:  2016-11-24       Impact factor: 5.773

Review 5.  Diabetes-mediated myelopoiesis and the relationship to cardiovascular risk.

Authors:  Tessa J Barrett; Andrew J Murphy; Ira J Goldberg; Edward A Fisher
Journal:  Ann N Y Acad Sci       Date:  2017-08       Impact factor: 5.691

6.  Circulating Blood Monocyte Subclasses and Lipid-Laden Adipose Tissue Macrophages in Human Obesity.

Authors:  Tal Pecht; Yulia Haim; Nava Bashan; Hagit Shapiro; Ilana Harman-Boehm; Boris Kirshtein; Karine Clément; Iris Shai; Assaf Rudich
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

Review 7.  Chemerin: A comprehensive review elucidating the need for cardiovascular research.

Authors:  David J Ferland; Stephanie W Watts
Journal:  Pharmacol Res       Date:  2015-07-23       Impact factor: 7.658

8.  Vitamin D deficiency in childhood obesity is associated with high levels of circulating inflammatory mediators, and low insulin sensitivity.

Authors:  M Reyman; A A Verrijn Stuart; M van Summeren; M Rakhshandehroo; R Nuboer; F K de Boer; H J van den Ham; E Kalkhoven; B Prakken; H S Schipper
Journal:  Int J Obes (Lond)       Date:  2013-05-20       Impact factor: 5.095

9.  Histidine supplementation improves insulin resistance through suppressed inflammation in obese women with the metabolic syndrome: a randomised controlled trial.

Authors:  R N Feng; Y C Niu; X W Sun; Q Li; C Zhao; C Wang; F C Guo; C H Sun; Y Li
Journal:  Diabetologia       Date:  2013-01-30       Impact factor: 10.122

Review 10.  Obesity and dementia: adipokines interact with the brain.

Authors:  Ilse A C Arnoldussen; Amanda J Kiliaan; Deborah R Gustafson
Journal:  Eur Neuropsychopharmacol       Date:  2014-03-20       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.